No Data
Hong Kong stock abnormal | Chang Xin Biology-B (02509) rose more than 7%, achieving revenue of 44.919 million yuan in the first half of the year. Previously reached a cooperation with huadong medicine.
China Good Biotech-B (02509) rose more than 7%, as of the time of publication, it increased by 7.54%, closing at 24.95 Hong Kong dollars.
QYUNS-B: 2024 INTERIM REPORT
Does Qyuns Therapeutics (HKG:2509) Have A Healthy Balance Sheet?
CICC: Maintains a "outperform" rating for Hansoh Pharma, with a target price raised to HK$21.12.
CICC released a research report stating that due to the increased down payment for cooperation and the thickening of performance, it raised the profit forecast for Hansoh Pharma (03692) in 2024 by 30.5% to 4.472 billion yuan, and raised the profit forecast for 2025 by 17.8% to 4.19 billion yuan. It maintains an "outperform industry" rating. Based on the SOTP valuation method, considering the upward revision of profit forecast and the temporary pressure on the company's generic drug sector, the target price is raised by 18.6% to 21.12 Hong Kong dollars. The company's current revenue is 6.506 billion yuan, a year-on-year increase of 44.2%; the net income attributable to the mother is 2.726 billion yuan, a year-on-year increase of 111.5%, and the performance is higher than the bank's expectations.
Qyuns Therapeutics Shrinks Loss in H1
Quantum Hi-Tech Biological Co., Ltd. (B) released its mid-year results, achieving a revenue of 44.919 million yuan and a gross profit of 37.756 million yuan.
Quanxin Biology-B (02509) announced its unaudited interim results for the six months ended June 30, 2024, with revenue of RMB 44.919 million, and no revenue in the same period last year; gross profit of RMB 37.756 million; R&D expenses of RMB 0.145 billion. The announcement stated that the revenue comes from authorization fees and R&D service fees for QX008N and QX004N authorized transactions, reflecting the Group's strong research and development capabilities.
No Data
No Data